University of Arkansas for Medical Sciences

iGlucose® Cellular RPM™ Shown Efficacious for Managing Diabetes Mellitus During Pregnancy

Retrieved on: 
Thursday, November 9, 2023
Women, General Health, Health, Diabetes, Medical Devices, Baby, Maternity, Consumer, Other Health, RPM, Woman, FDA, Pregnancy, Physician, University of Arkansas for Medical Sciences, Type 1, Medicine, Type 2, University, Type 2 diabetes, Vital signs, Patient, Blood, UAMS, Medical device, Medical imaging

A recently published research study from the University of Arkansas for Medical Sciences concluded that using cellular-enabled RPM™ glucose meters is valuable in managing Type 1 diabetes mellitus and Type 2 diabetes mellitus during pregnancy.

Key Points: 
  • A recently published research study from the University of Arkansas for Medical Sciences concluded that using cellular-enabled RPM™ glucose meters is valuable in managing Type 1 diabetes mellitus and Type 2 diabetes mellitus during pregnancy.
  • Participants who used the iGlucose® glucose meter demonstrated increased positive appraisal of diabetes and general life satisfaction.
  • In addition, participants scored the cellular RPM™ iGlucose® device high on both system usability and satisfaction.
  • The overall feedback on the iGlucose® glucose meter, the gold standard in cellular RPM™ glucose meters since receiving FDA approval in 2016, was positive across multiple evaluation points.

Foot and Ankle Orthopaedic Surgeons Change Lives in Kenya

Retrieved on: 
Tuesday, November 7, 2023
Human, MD, University of Arkansas for Medical Sciences, Volunteering, Foot, Medicine, Surgeon, University, Travel, Disability, Ankle, American Orthopaedic Foot and Ankle Society, Patient, AIC, Nursing

Rosemont, Ill., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Volunteers from the American Orthopaedic Foot & Ankle Society (AOFAS) traveled to Kenya to provide life-changing surgery to patients with lower extremity deformities and disabilities as part of the Orthopaedic Foot & Ankle Foundation Overseas Outreach Project to Kenya.

Key Points: 
  • Rosemont, Ill., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Volunteers from the American Orthopaedic Foot & Ankle Society (AOFAS) traveled to Kenya to provide life-changing surgery to patients with lower extremity deformities and disabilities as part of the Orthopaedic Foot & Ankle Foundation Overseas Outreach Project to Kenya.
  • Over five days, the duo completed more than 30 corrective foot and ankle surgeries and provided additional consultations for Kenyan adults and children.
  • In-country expenses were covered by the Orthopaedic Foot & Ankle Foundation , supported by a grant from Stryker.
  • To learn more about the Orthopaedic Foot & Ankle Foundation Overseas Outreach Projects, visit aofas.org/foundation .

PharmAla Receives First Office Action for PharmAla-1 PCT Filing

Retrieved on: 
Monday, September 25, 2023
BIO, Intellectual property, Ontario Centre of Forensic Sciences, Partnership, CSE, University, P-1, Prior art, Medicine, University of Arkansas for Medical Sciences, Medication, MDXX, Innovation, Research, Patent Cooperation Treaty, PCT, CNS, Central nervous system, OTC, Toxicology, MDMA, Pharmacology, Safety, Pharmaceutical industry

VANCOUVER, British Columbia, Sept. 25, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is proud to announce that it has received the first office action from the Patent Cooperation Treaty (PCT) filing for the company’s novel PharmAla-1 (P-1) molecule.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 25, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is proud to announce that it has received the first office action from the Patent Cooperation Treaty (PCT) filing for the company’s novel PharmAla-1 (P-1) molecule.
  • “The generation of novel intellectual property is incredibly important for drug discovery companies like PharmAla.
  • This First Office Action for P-1 shows that our drug discovery pipeline yields novel, inventive molecules with significant value as neuropsychiatric therapeutics,” said Nick Kadysh, CEO, PharmAla Biotech.
  • “Our development pipeline, which can yield new molecules appropriate for pre-clinical development, is an incredible asset for PharmAla.

TODAY’s Al Roker, Congressman Jamie Raskin, and congressional spouses Patricia Garamendi and Martha McKenzie Hill honored by Prevent Cancer Foundation’s Congressional Families Program

Retrieved on: 
Friday, September 15, 2023
Member of Congress, Fox News, Medicine, Prostate-specific antigen, Winthrop, Independent Payment Advisory Board, University, Congressional Club, Prostate cancer, Cancer, Human, Black, John Garamendi, Advisory board, University of Arkansas for Medical Sciences, Congress, National Cancer Institute, Museum of Black Arkansans and Performing Arts Center, NASA Distinguished Service Medal, Op-ed, Risk, Humour, Spouse, Diagnosis, III, PSA, Pharmaceutical industry, Nursing, Journalism

Washington, D.C., Sept. 15, 2023 (GLOBE NEWSWIRE) -- The Prevent Cancer Foundation’s Congressional Families Cancer Prevention Program® held its 30th Annual Action for Cancer Awareness Awards luncheon on Thursday, September 14 on Capitol Hill.

Key Points: 
  • Washington, D.C., Sept. 15, 2023 (GLOBE NEWSWIRE) -- The Prevent Cancer Foundation’s Congressional Families Cancer Prevention Program® held its 30th Annual Action for Cancer Awareness Awards luncheon on Thursday, September 14 on Capitol Hill.
  • The theme of this year’s event was “Early Detection = Better Outcomes,” in recognition of the Prevent Cancer Foundation’s rallying cry on the importance of routine cancer screenings to detect cancer early.
  • Fox News Chief National Correspondent and Prevent Cancer Foundation board member Jennifer Griffin served as the master of ceremonies.
  • Patricia Garamendi (married to Congressman John Garamendi, California)
    Patricia Garamendi is a longtime member and leader of the Congressional Families Program Advisory Committee.

NEW TREATMENTS PROVIDE MORE OPTIONS FOR PEOPLE WITH ALOPECIA AREATA

Retrieved on: 
Tuesday, August 15, 2023
Hair, Asthma, University, Eyelash, Hair loss, JAK, Medicine, Dermatitis, University of Arkansas for Medical Sciences, Marten, Silver, Immunodeficiency, Cancer, Clinical trial, Nail, Journal of the American Academy of Dermatology, Hope, Head, Methotrexate, American Academy, Inflammation, FAAD, Scalp, Down syndrome, Alopecia areata, Eyebrow, Journal, MD, Patient, Immune system, Thyroid disease, DR, Vitiligo, Nivolumab, Disease, Pharmaceutical industry, Medical device, Dermatology

ROSEMONT, Ill., Aug. 15, 2023 /PRNewswire/ -- A study published today in a supplement of the Journal of the American Academy of Dermatology titled "Alopecia: A New Frontier" reveals that a new type of medication called JAK inhibitors can effectively treat moderate to severe alopecia areata – a type of hair loss – that has historically been difficult to treat.

Key Points: 
  • "The development of JAK inhibitors has given us another treatment to improve the lives of patients with alopecia areata."
  • The most common sign of alopecia areata is often sudden hair loss, Dr. Johnson said.
  • Having other medical conditions such as asthma, hay fever, eczema, thyroid disease, vitiligo, and Down syndrome also increases a person's risks for developing alopecia areata.
  • "We now have more treatment options than ever before for alopecia areata patients, and they are providing results for people for whom previous treatments were not effective," said Dr. Johnson.

PharmAla Files Patent for Novel MDXX Molecule PharmAla-1

Retrieved on: 
Monday, July 31, 2023
ABA, University, Autumn, Ontario Centre of Forensic Sciences, Partnership, CSE, Spectrum, Autism spectrum, Medicine, University of Arkansas for Medical Sciences, MDXX, Hope, Innovation, Research, Composition of matter, IP, Computational chemistry, CNS, Drug design, Central nervous system, MDMA, Patent, ASD, NCE, ALA, Psychedelic drug, OTC, Drug discovery, Psychiatry, Social anxiety, Safety, Pharmaceutical industry, Pharmacology

PharmAla’s novel drug development pipeline has been advancing rapidly in 2023, with PharmAla’s ALA family moving rapidly into clinical development.

Key Points: 
  • PharmAla’s novel drug development pipeline has been advancing rapidly in 2023, with PharmAla’s ALA family moving rapidly into clinical development.
  • The Composition of Matter patent on the Novel Chemical Entity (NCE) PharmAla-1 will further strengthen the company’s position as a leading developer of Central Nervous System (CNS) pharmaceutical treatments.
  • PharmAla-1 is the first molecule of PharmAla’s extensive computational drug development pipeline, which PharmAla is announcing to the market in detail; PharmAla’s ALA and ABA patent families were developed via traditional drug discovery.
  • PharmAla is also excited to announce the acceptance of its review article titled "Balancing therapeutic efficacy and safety of MDMA and novel MDXX analogues as novel treatments for autism spectrum disorder" for publication in Psychedelic Medicine.

Inspire Medical Systems, Inc. Announces the Addition of Charisse Y. Sparks, M.D. as Chief Medical Officer

Retrieved on: 
Monday, July 31, 2023
Employment, University, Medicine, University of Arkansas for Medical Sciences, Sleep, OSA, University of Kansas School of Medicine, Harvard Medical School, Pain, Nose, Patient, ACS, Physician, Oklahoma Office of the Chief Medical Examiner, DePuy Synthes, Charisse, Trauma, Obstructive sleep apnea, NYSE, Management, Nursing, Inspiration

As Chief Medical Officer, Dr. Sparks will be a member of Inspire’s executive leadership team and will lead the Company’s medical and clinical affairs functions.

Key Points: 
  • As Chief Medical Officer, Dr. Sparks will be a member of Inspire’s executive leadership team and will lead the Company’s medical and clinical affairs functions.
  • Dr. Sparks will report to Tim Herbert, President and Chief Executive Officer of the Company.
  • “We are excited to add Dr. Sparks, a board-certified physician with extensive business and leadership experience, to our executive team,” said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems.
  • "Inspire has long-partnered with leading ear, nose, and throat surgeons, and sleep physicians, as part of our medical advisory boards.

NFID Names Robert H. Hopkins, Jr., MD, as Medical Director

Retrieved on: 
Thursday, July 20, 2023
Vaccine, National Foundation for Infectious Diseases, Immunization, CAE, University, Hopkins, Education, Internal medicine, Human services, Public, Pediatrics, University of Arkansas for Medical Sciences, Advisory Committee, Medicine, UAMS, Human, Infection, Advisory Committee on Immunization Practices, Korea Disease Control and Prevention Agency, Growth, American College, NFID, Pharmaceutical industry, Management, Nursing, MD

BETHESDA, Md., July 20, 2023 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the appointment of Robert H. Hopkins, Jr., MD, as its new medical director.

Key Points: 
  • BETHESDA, Md., July 20, 2023 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the appointment of Robert H. Hopkins, Jr., MD, as its new medical director.
  • Hopkins succeeds William Schaffner, MD, who served NFID for many years and will continue to serve as an NFID spokesperson, lending his expertise to NFID initiatives.
  • As medical director, Hopkins will focus on the growth of NFID programs, including efforts to build vaccine confidence, address health equity issues, increase awareness of disease prevention and treatment, and strengthen NFID partner collaborations.
  • In his role as NFID medical director, Hopkins will also serve as an ex-officio member of the NFID Board of Directors and all Board-level committees.

Targeted Oncology™ announces recipients of its Q2 Oncology Icons award program

Retrieved on: 
Tuesday, July 18, 2023
Brain, Cleveland Clinic, Lake Erie College of Osteopathic Medicine, Osteopathic medicine in the United States, University, Internal medicine, D.O, Medicine, University of Arkansas for Medical Sciences, Physician, FACP, American Board of Internal Medicine, Mission, Medical college, Multimedia, Research, Oncology, Medical College of Wisconsin, American Board of Commissioners for Foreign Missions, Cancer, Patient, Baptist Health, Hematology, Lake Erie College, American College, Cleveland, Health, Society, Nursing

CRANBURY, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Targeted Oncology, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of oncology, is pleased to announce the honorees of the Oncology Icons Q2 award program.

Key Points: 
  • CRANBURY, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Targeted Oncology, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of oncology, is pleased to announce the honorees of the Oncology Icons Q2 award program.
  • Through their unwavering commitment, these Oncology Icons have played a vital role in transforming the industry and improving outcomes for patients nationwide.
  • “We are truly honored to recognize these exceptional individuals as icons in the field of oncology,” said Erik Lohrmann, vice president of Targeted Oncology.
  • Submissions for the Oncology Icons award program are accepted on a rolling basis throughout the year.

MeTree&You to work with Arkansas Department of Health and the University of Arkansas Health Sciences to drive improved health outcomes and consumer wellness

Retrieved on: 
Tuesday, June 20, 2023
Roflumilast, Genetic variation, Duke University, University, Diabetes, Cone Health, Genetics, Arkansas Department of Health, University of Arkansas for Medical Sciences, Stroke, Natural State, Cancer, Risk assessment, University of North Carolina at Charlotte, PHD, APRN, ETSU/Mountain States Health Alliance Athletic Center, SHARE, Patient, Collection, Risk, Department of Defense Serum Repository, Health, Death, Alzheimer's disease, Health information exchange, Kidney disease, Disease, Nursing, Pharmaceutical industry, Museum of Black Arkansans and Performing Arts Center, Medicine

DURHAM, N.C., June 20, 2023 /PRNewswire-PRWeb/ -- MeTree&You (www.metreeandyou.com) is pleased to announce that it has been selected to incorporate family health history clinical support programming into well-patient appointments to assist healthcare providers. The University of Arkansas Health Sciences will utilize the MeTree&You (MeTree) family health history tool in conjunction with the Arkansas Department of Health's State Health Alliance for Records Exchange (SHARE) to identify patients at increased risk for genetically influenced diseases. The results will provide guidance to healthcare providers through evidence-based algorithms on appropriate genetic screening, further testing and referrals matched to the patient's level of risk.

Key Points: 
  • The University of Arkansas Health Sciences will utilize the MeTree&You (MeTree) family health history tool in conjunction with the Arkansas Department of Health's State Health Alliance for Records Exchange (SHARE) to identify patients at increased risk for genetically influenced diseases.
  • The University of Arkansas Health Sciences will utilize the MeTree&You (MeTree) family health history tool in conjunction with the Arkansas Department of Health's State Health Alliance for Records Exchange (SHARE) to identify patients at increased risk for genetically influenced diseases.
  • The results will provide guidance to healthcare providers through evidence-based algorithms on appropriate genetic screening, further testing and referrals matched to the patient's level of risk.
  • This will represent the first public health collaboration with a health information exchange for MeTree.